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Abstract:  
 
Castleman’s Disease is a rare lymphoproliferative disorder with two distinctly defined clinical forms. 
While multi-centric Castleman’s disease (MCD) poses a potential therapeutic challenge, unicentric 
variant (UCD) has historically been considered curable with surgical resection. Hence, little is known 
to guide management of patients with UCD, refractory to surgical resection and combination 
chemotherapy. We present a case of a patient, negative for HIV and HHV-8, who had an 
unsuccessful surgical intervention and no response to radiotherapy and chemotherapy. He had 
severe paraneoplastic pemphigus and was treated with tocilizumab, an anti-interleukin-6 receptor 
monoclonal antibody that has demonstrated good response rates in MCD, but demonstrated no 
clinical response despite two months of treatment. Our report is the first to describe a lack of 
response to tocilizumab in the rare setting of refractory UCD and discuss potential for distinct 
disease biology. 
 
 CASE REPORT: 
Introduction: 
Castleman’s disease (CD) is a rare lymphoproliferative disorder thought to be mediated via 
autoinflammation, cytokine release and viral co-infections 1. CD represents a heterogeneous group 
of diseases and is stratified based on centricity and pathology. Two well-defined clinical subtypes 
include localized or unicentric CD (UCD) and systemic or multicentric CD (MCD) and three main 
histological variants consist of hyaline vascular type (80-90%), plasma cell type (10%-20%) and mixed 
type (<5%) 2,3. MCD can further be subdivided by the presence or absence of viral co-infection with 
human herpes virus-8 (HHV-8) and human Immunodeficiency virus (HIV). Conventionally, the 
prognosis for UCD is excellent whereas the outlook for MCD is worse, typically when associated with 
HIV and HHV-8 4.  
The most common presenting complaint of UCD is isolated lymphadenopathy, although symptoms 
related to mass effects on surrounding structures may be present. A systematic review of 278 cases 
of UCD identified that the mean size of involved lymph nodes at baseline was 5.5 cm, compared to 
3.8 cm for MCD cases 5. The UCD case presented here had a baseline size of 6 cm. MCD commonly 
presents with systemic symptoms including traditional ‘B symptoms’ such as fever, night sweats and 
weight loss, along with generalized lymphadenopathy and splenomegaly.  
The understanding of the pathogenesis of CD remains limited. Albeit CD had been considered to 
originate from polyclonal sources, mainly HIV- and HHV-8- driven, recent evidence suggests that at 
least a proportion of cases have a monoclonal origin 6-8. Based on recent therapeutic evidence, 
excessive cytokine release has gained attention as the key mechanism of pathogenesis as well as 
symptomatology. The dysregulation of interleukin-6 (IL-6) has been implicated in both UCD and MCD 
and hypersecretion of IL-6 by germinal center B-cells is considered to be responsible for systemic 
manifestations 9. IL-6 regulates T-cell function, acute phase reaction and terminal B-cell 
differentiation 10, 11.  
The optimal therapeutic strategy for MCD is unclear. A range of systemic therapies including 
steroids, cytotoxic chemotherapy-single agent or combination regimens such as CHOP, anti-CD20 
monoclonal antibodies, bortezomib, antiviral agents and IL-6 inhibitors such as tocilizumab have 
been utilized with varying degrees of success 4, 12. 
The standard of care for UCD is surgical resection, with 10-year OS rates exceeding 95% 5. Data 
remains scarce where complete surgical resection is not possible or remains unsuccessful. 
 Alternative treatments include debulking surgery, neoadjuvant systemic chemotherapy or rituximab. 
Radiotherapy remains an option for unresectable cases, but with mixed results 13, 14.  
Case presentation: 
A 46-year-old African male, with no past medical history of significance, presented to another 
hospital with an 18 months history of worsening right-sided chest pain, malaise and B-
symptoms. Physical examination did not reveal any anemia, pallor, jaundice, lymphadenopathy 
or hepatosplenomegaly. The respiratory examination was remarkable for decreased breath 
sounds in the right apex with minimal tracheal deviation to the ipsilateral side. Full blood count, 
liver and renal function tests and ferritin were normal. CRP level was elevated at 39 mg/L and 
LDH 339 IU/L. Serum albumin was 31 g/L and paraproteins were normal. A computed 
tomography (CT) scan showed a 6x6x7 cm right upper lobe mass [Figure 1] and a CT-guided 
biopsy revealed the diagnosis of unicentric Castleman’s disease (UCD) of hyaline vascular variant 
[Figure 2]. HIV and HHV-8 were negative and no paraprotein was detected. Four cycles of 
weekly rituximab were given, primarily to debulk the mass. At that point, the patient moved to 
our area and presented to our service. 
A repeat CT scan did not show any interval decrease in the size of the mass. A right-sided 
thoracotomy, with attempted curative resection of the mass, was abandoned due to massive 
hemorrhage necessitating a salvage angioembolization of the feeding vessels. Following a case 
review, further cardiothoracic surgery was deemed high risk; radical radiotherapy (40Gy in 20 
fractions) was therefore administered.  One month after completion of radiotherapy, there was 
only modest reduction in tumor size and his chest discomfort persisted.  No further active 
therapy was planned at that point.  
Three months after completion of radiotherapy, the patient was admitted with progressive, 
painful blistering of oral mucous membranes and lip vermillion, requiring nutritional support 
and parenteral pain relief. Paraneoplastic pemphigus (PNP) was diagnosed, based on clinical 
grounds, and he was treated with high dose pulsed steroids and Mycophenolate Mofetil, up to 
1.5 gram/day, without response. The condition progressed with severe involvement of oral, 
pharyngeal and genital mucous membranes, hair loss, spreading lichenoid and blistering 
eruption of the skin, eventually affecting >75% of the total skin surface.   
Further discussions regarding potentially curative surgery were held but he was deemed unfit 
for such major and risky surgery. He was therefore given a trial of combination chemotherapy 
with R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone). The 
 first cycle was complicated by significant sepsis, with no clinical or radiologic improvement in 
the underlying UCD or PNP. 
Given his primary refractory disease and poor state of health due to progressive pemphigus, he 
was deemed unsuitable for further chemotherapy. Evidence from tocilizumab activity in MCD 
was extrapolated and he received four cycles of tocilizumab at a dose of 8mg/kg every two 
weeks. He demonstrated no clinical or radiological response after two months of treatment and 
remained as an inpatient through the course for pain relief and parenteral nutrition. The 
decision was made to switch to palliative management and he died a week later.  
Discussion/Conclusion: 
Tocilizumab is a recombinant, humanized monoclonal antibody that blocks the IL-6 receptors, both 
soluble and membrane-bound, and hence blocks downstream intracellular signalling 15, 16. Promising 
results have been reported with the use of tocilizumab in patients with MCD. A major, multi-centre 
trial of 28 patients reported that tocilizumab, given at a dose of 8mg/kg fortnightly, resulted in a 
significant reduction in lymphadenopathy for 52% of patients after one year of treatment and a 
median follow-up of 15 months. Biochemical improvement in inflammatory markers was also noted 
17. Three small case series, using the same regimen of tocilizumab and each including 2-3 patients, 
reported an overall response rate of 100% with a follow-up ranging up to four years 18-20. Tocilizumab 
has also been reported to be beneficial in PNP associated with MCD 10. 
The case presented here had refractory UCD, an entity with an extreme paucity of data, owing to its 
rarity. The refractory UCD was not amenable to surgery at the outset and did not respond to 
neoadjuvant rituximab, radiotherapy and systemic chemotherapy with R-CHOP. The effectiveness of 
tocilizumab in treating MCD coupled with the pre-existing knowledge that IL-6 is dysregulated 
universally in MCD made the prospect of using it for UCD enticing. However, tocilizumab did not 
result in clinical benefit in this case. Disappointingly, there was also no clinical response of his PNP to 
tocilizumab. PNP has been reported as an independent adverse prognostic factor in a large single-
center review of CD including 114 patients of which 62 (54%) had UCD. Of the 37 patients with PNP, 
32 had UCD 21.  
Though cases of refractory course of UCD have occasionally been reported 22-23, this report is the first 
of refractory UCD treated with tocilizumab, to the best of our knowledge. Since the success rate for 
complete surgical resection has been remarkable in UCD, data is lacking on alternate therapies for 
disease not amenable to resection. In this patient, tocilizumab was not effective in treating 
refractory UCD. Whether association with PNP or lack of clinically significant follow-up confounded 
 delineation of its true efficacy, it would be worthwhile exploring if IL-6 pathway plays as 
fundamental a role in UCD as is reported in MCD. This report further highlights a need for in-depth 
understanding of UCD and its clonal derivation and hints that some of the cases may be neoplastic 
right from outset.  
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 Figure Legends: 
Figure 1: Chest Computed Tomography,     A) Coronal view    B) Axial view. 
CT scan of the chest shows a right apical, vascular mass measuring  6x6x7cm, with no accompanying 
mediastinal lymphadenopathy.  
 
Figure 2: Hyaline vascular variant of Castleman’s disease (CD) 
A) Hyaline vascular variant (H+E x200): Hyalinised germinal centre containing atypical follicular 
dendritic cells with ‘onion-skinning’ by surrounding lymphocytes. 
B) Immunohistochemical staining of lung mass (X 200) for CD23 highlights follicular dendritic 
cell clusters within an expanded mantle zone of CD23-positive cells.  
 
Figure 3: Paraneoplastic pemphigus (PNP) 
Photomicrographs show involvement of mucous membranes, hair loss, spreading lichenoid and 
blistering eruption of the skin. 
Abbreviations: Castleman’s disease (CD), Paraneoplastic pemphigus (PNP) 
 
